The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
Open accessAbstract
Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent therapies targeting Aβ clearance using anti-Aβ monoclonal antibodies (mabs) during the early stages of AD provide minimal cognitive benefit”
From Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration (2024) · cites this paper as Shi et al. 2022
In the citing paper
“Studies have shown that Aβ buildup can start 15–20 years before clinical symptoms appear, indicating that therapy effectiveness may depend on early intervention [88,89].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 42
RetractedClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Research works printed but not linked: 3
- 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE).
- 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE).
- Swanson, 2018, Clinical and biomarker updates from BAN2401 Study 201 in early AD, Proceedings of Clinical Trials on Alzheimer’s Disease Conference
Cited by
Sorted by citations
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M. C., Kramer, L. D., & Bateman, R. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01124-2 · Cited by 328
Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics
Dhapola, R., Beura, S. K., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09021-z · Cited by 288
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 256
Human Microglia Show Unique Transcriptional Changes in Alzheimer's Disease
Prater, K. E., Green, K. J., Mamde, S., Sun, W., Cochoit, A., Smith, C. L., Chiou, K. L., Heath, L., Rose, S. E., Wiley, J., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00424-y · Cited by 164
Wu, W., Ji, Y., Wang, Z., Wu, X., Li, J., Gu, F., Chen, Z., & Wang, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01512-w · Cited by 150
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 88
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 82
Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases
Yuan, C., He, Y., Xie, K., Feng, L., Gao, S., & Cai, L. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1282431 · Cited by 87
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
Ghosh, S., Ali, R., & Verma, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124231 · Cited by 79
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
Pei, J., Palanisamy, C. P., Natarajan, P. M., Umapathy, V. R., Roy, J. R., Srinivasan, G. P., Panagal, M., & Jayaraman, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102393 · Cited by 73
Kee, T. R., Khan, S. A., Neidhart, M. B., Masters, B. M., Zhao, V. K., Kim, Y. K., Percy, K. C. M., & Woo, J. A. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01144-4 · Cited by 68
Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 62
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 60
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 60
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Studies have shown that A β buildup can start 15–20 years before clinical symptoms appear, indicating that therapy effectiveness may depend on early intervention [88,89].”
BackgroundCurrent understanding of metal-dependent amyloid-β aggregation and toxicity
Yi, Y., & Lim, M. H. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00208f · Cited by 50
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 49
Asghar, S., Mushtaq, N., Ahmed, A., Anwar, L., Munawar, R., & Akhtar, S. (2024) · Molecules · doi:10.3390/molecules29020490 · Cited by 48
Resveratrol as a Therapeutic Agent in Alzheimer’s Disease: Evidence from Clinical Studies
Puranik, N., Kumari, M., Tiwari, S., Dhakal, T., & Song, M. (2025) · Nutrients · doi:10.3390/nu17152557 · Cited by 48
Small-molecule theranostics in Alzheimer's disease
Sarabia‐Vallejo, Á., López‐Alvarado, P., & Menéndez, J. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115382 · Cited by 48
Kosmopoulou, D., Lafara, M.-P., Adamantidi, T., Ofrydopoulou, A., Grabrucker, A. M., & Τσούπρας, Α. (2024) · Applied Sciences · doi:10.3390/app14156417 · Cited by 45
Puranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 49
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 46
Biomarkers for Managing Neurodegenerative Diseases
Cheslow, L., Snook, A. E., & Waldman, S. A. (2024) · Biomolecules · doi:10.3390/biom14040398 · Cited by 41
Lorenzo, D. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400180 · Cited by 46
Pyka, P., Haberek, W., Więcek, M., Szymańska, E., Ali, W., Cios, A., Jastrzębska‐Więsek, M., Satała, G., Podlewska, S., Giacomo, S. D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02148 · Cited by 39
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Factors affecting the GABAergic synapse function in Alzheimer’s disease: Focus on microRNAs
Rivera, J., Sharma, B., Torres, M. M., & Kumar, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102123 · Cited by 38
Schweickart, A., Batra, R., Neth, B. J., Martino, C., Shenhav, L., Zhang, A. R., Shi, P., Karu, N., Huynh, K., Meikle, P. J., et al. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00016-3 · Cited by 36
Shen, Y., Liu, F., & Zhang, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117235 · Cited by 36
Shastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 34
Tran, J., Parekh, S., Rockcole, J., Wilson, D., & Parmar, M. S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123001 · Cited by 35
Ferroptosis and pathogenesis of neuritic plaques in Alzheimer disease
Streit, W. J., Phan, L. T., & Bechmann, I. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000823 · Cited by 36
Dominguez-Gortaire, J. A., Ruiz, A., Porto-Pazos, A. B., Rodríguez, S., & Cedrón, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031004 · Cited by 35
Chen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 35
Arroyo-Pacheco, N., Sarmiento-Blanco, S., Vergara-Cadavid, G., Castro-Leones, M., & Contreras‐Puentes, N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102620 · Cited by 37
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 33
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 35
Lecanemab: More Questions Than Answers!
Kaur, U., Reddy, J., Tiwari, A., Chakrabarti, S., & Chakrabarti, S. S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01331-1 · Cited by 30
Singh, K., Gupta, J. K., Kumar, S., & Soni, U. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037275221240327042353 · Cited by 32
The Irony of Iron: The Element with Diverse Influence on Neurodegenerative Diseases
Lee, S., & Kovács, G. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084269 · Cited by 30
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Small Extracellular Vesicles’ miRNAs: Biomarkers and Therapeutics for Neurodegenerative Diseases
Lim, W. Q., Michelle Luk, K. H., Lee, K. Y., Nurul, N., Loh, S. J., Yeow, Z. X., Wong, Q. X., Daniel Looi, Q. H., Chong, P. P., How, C. W., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041216 · Cited by 25
Li, J., Ebrahimi, A., & Ali, A. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105169 · Cited by 27
Designing multi-target-directed flavonoids: a strategic approach to Alzheimer's disease
Park, S., Kim, M., Lin, Y., Hong, M., Nam, G., Mieczkowski, A., Kardos, J., Lee, Y., & Lim, M. H. (2023) · Chemical Science · doi:10.1039/d3sc00752a · Cited by 27
Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Nystuen, K., McNamee, S. M., Akula, M., Holton, K. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11010045 · Cited by 28
Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
Kim, H. R., Taslakjian, B., Kim, S., Tirrell, M., & Guler, M. O. (2024) · ChemBioChem · doi:10.1002/cbic.202300831 · Cited by 27
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116684 · Cited by 26
Marei, H. E. S., Khan, M. U. A., & Hasan, A. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00504-2 · Cited by 27
Sharma, M., Tanwar, A. K., Purohit, P. K., Pal, P., Kumar, D., Vaidya, S., Prajapati, S. K., Kumar, A., Dhama, N., Kumar, S., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105685 · Cited by 27
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 28
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
Martins, A. C., Oshiro, M. Y., Alberício, F., & de la Torre, B. G. (2024) · Biomedicines · doi:10.3390/biomedicines12091992 · Cited by 25
Abelein, A., & Johansson, J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00040k · Cited by 25
Choi, M., Ryu, J., Vu, H. D., Kim, D., Youn, Y.-J., Park, M. H., Huynh, P. T., Hwang, G.-B., Youn, S. W., & Jeong, Y. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914954 · Cited by 25
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 25
PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier
Szecskó, A., Mészáros, M., Simões, B. T., Cavaco, M. C., Chaparro, C. I. P., Porkoláb, G., Castanho, M. A. R. B., Deli, M. A., Neves, V., & Veszelka, S. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00641-0 · Cited by 24
Wang, H., Pan, J., Zhang, M., & Tan, Z. F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599048 · Cited by 28
Amyloid futures in the expanding pathology of brain aging and dementia
Thorwald, M. A., Silva, J. A., Head, E., & Finch, C. E. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12896 · Cited by 24
Cheng, J.-L., Tan, C., Liu, H.-Y., Han, D., & Liu, Z. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i9.607 · Cited by 24
Gohel, D., Zhang, P., Gupta, A. K., Li, Y., Chiang, C., Li, L., Hou, Y., Pieper, A. A., Cummings, J. L., & Cheng, F. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231391 · Cited by 25
Yu, T., Xing, Y., Gao, Q., Wang, D., Chen, H., Wang, H., & Zhang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122746 · Cited by 22
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease
Park, J., Simpson, C., & Patel, K. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231218253 · Cited by 25
Disease-Modifying Treatments and Their Future in Alzheimer’s Disease Management
Smith, B., & Ownby, R. L. (2024) · Cureus · doi:10.7759/cureus.56105 · Cited by 22
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Xing, C., Chen, H., Bi, W., Lei, T., Hang, Z., & Du, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413446 · Cited by 21
Mohammed, A. A., Barale, S. S., Kamble, S. A., Paymal, S. B., & Sonawane, K. D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124880 · Cited by 21
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys
Tu, Z., Yan, S., Han, B., Li, C., Liang, W., Lin, Y., Ding, Y., Wei, H., Wang, L., Xu, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01601-6 · Cited by 20
Iram, F., Shahid, M., Ansari, J., Ashraf, G. M., Hassan, M. I., & Islam, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102342 · Cited by 20
Babygirija, R., Sonsalla, M. M., Mill, J., James, I., Han, J. H., Green, C. L., Calubag, M. F., Wade, G., Tobon, A., Michael, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49589-z · Cited by 22
Singh, G., Kumar, S., Panda, S. R., Kumar, P., Rai, S., Verma, H., Singh, Y. P., Kumar, S., Srikrishna, S., Naidu, V. G. M., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00130 · Cited by 19
Tyrakis, P., Agridi, C., & Kourti, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168630 · Cited by 19
Methods for analyzing the coordination and aggregation of metal–amyloid-β
Park, S., Na, C., Han, J., & Lim, M. H. (2023) · Metallomics · doi:10.1093/mtomcs/mfac102 · Cited by 19
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer’s Disease Treatment
Knight, E., Geetha, T., Broderick, T. L., & Babu, J. R. (2023) · Metabolites · doi:10.3390/metabo13030438 · Cited by 20
Lutshumba, J., Wilcock, D. M., Monson, N. L., & Stowe, A. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106202 · Cited by 20
APOE genotype and sex modulate Alzheimer’s disease pathology in aged EFAD transgenic mice
Balu, D., Valencia‐Olvera, A. C., Islam, Z., Mielczarek, C., Hansen, A. L., Ramos, T. M. P., York, J. M., LaDu, M. J., & Tai, L. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1279343 · Cited by 20
Innovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease
Park, J. M., & Tsai, L. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003046 · Cited by 19
Khan, B., Iqbal, M. K., Khan, M. A., Khan, H. R., Kiyani, M. M., Bashir, S., & Li, S. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02337-4 · Cited by 17
Gugliandolo, A., Blando, S., Salamone, S., Caprioglio, D., Pollastro, F., Mazzon, E., & Chiricosta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076598 · Cited by 18
Azargoonjahromi, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae066 · Cited by 17
Joynes, C. M., Bilgel, M., An, Y., Moghekar, A., Ashton, N. J., Kac, P. R., Karikari, T. K., Blennow, K., Zetterberg, H., Thambisetty, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14405 · Cited by 18
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 18
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration
Logsdon, A. F., Foresi, B., Hu, S. J., Quah, E., Meuret, C. J., Le, J. P., Hendrickson, A. S., Redford, I. K., Kumar, A., Phan, B. A., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16067 · Cited by 16
Biosensing strategies for amyloid‐like protein aggregates
Zhou, Y., Yan, S., Dong, W., Wu, C., Zhao, Z., Wang, R., Duo, Y., Huang, Y., Xu, D., & Jiang, C. (2024) · BMEMat · doi:10.1002/bmm2.12053 · Cited by 16
New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
Bon, L., Banaś, A., Dias, I., Melo-Marques, I., Cardoso, S. M., Chaves, S., & Santos, M. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020281 · Cited by 16
Roberts, W. S., Price, S., Wu, M., & Parmar, M. S. (2024) · Cureus · doi:10.7759/cureus.67037 · Cited by 17
Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer’s Disease
Abdelhamid, M., Counts, S., Zhou, C., Hida, H., Kim, J., Michikawa, M., & Jung, C. (2025) · Nutrients · doi:10.3390/nu17030558 · Cited by 16
Brain-targeted intranasal delivery of biologics: a perspective for Alzheimer's disease treatment
Li, H., Shen, X., Zhang, B., Li, Y., Alexander, C., Harvey, P., & Zhu, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00148j · Cited by 18
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Perna, A., Montine, K. S., White, L. R., Montine, T. J., & Cholerton, B. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01441-w · Cited by 16
Coto-Vilcapoma, A., Castilla‐Silgado, J., Fernández‐Garcia, B., Pinto-Hernández, P., Cipriani, R., Capetillo‐Zarate, E., Menéndez‐González, M., Vega, M. A. Á., & Tomás‐Zapico, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169256 · Cited by 15
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 15
Chen, X., Becker, A., Albay, R., Nguyen, P. D., Karachentsev, D., Roberts, A. J., Rynearson, K. D., Tanzi, R. E., & Mobley, W. C. (2024) · Annals of Neurology · doi:10.1002/ana.26958 · Cited by 14
Angelopoulou, E., Bougea, A. M., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2024) · Cells · doi:10.3390/cells13131164 · Cited by 15
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Sandoval, K. E., & WITT, K. A. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001117 · Cited by 14
Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?
Flynn, C. M., & Yuan, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1159314 · Cited by 15
The role of peripheral innate immune cells in Alzheimer’s disease progression
Cao, Y., Tang, K., Ma, P., Zhang, R., Yang, Y., Li, T., Zhang, Y., & Peng, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616939 · Cited by 15
Cai, J., Xie, D., Kong, F., Zhai, Z., Zhu, Z., Zhao, Y., Xu, Y., & Sun, T. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231249 · Cited by 13
Metadata
- Authors
- Shi, M., Chu, F., Zhu, F., & Zhu, J.
- Affiliations
- First Hospital of Jilin University (CN)
- Shenzhen University (CN)
- Karolinska University Hospital (SE)
- Corresponding author
- Zhu, Feiqi
- Zhu, Jie
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-04-12
- Volume
- 14
- Pages
- 870517-870517
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC9039457
- OpenAlex
- W4223533048
- Cited by
- 275
- References
- 97
- Citations by year
- 2026: 28 · 2025: 66 · 2024: 104 · 2023: 68 · 2022: 8
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- People's Government of Jilin Province
- Jilin University
- Sanming Project of Medicine in Shenzhen (SZSM201801014)
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid beta monoclonal antibody, aducanumab, lecanemab, amyloid plaques, disease-modifying therapy, immunotherapy, clinical trial results, adverse effects, amyloid-beta clearance, tau hyperphosphorylation, neurofibrillary tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
